Vertex Pharmaceuticals (NASDAQ: VRTX) has been designated Bernstein's top biotech stock pick by analyst Jeffrey Walch following the failure of a rival drug trial. The assessment comes after Sionna's SION-719 candidate, evaluated in the PreciSION CF phase 2a proof-of-concept study, missed its primary endpoint in cystic fibrosis patients already receiving Vertex's Trikafta therapy.
The trial recorded a mean placebo-adjusted sweat chloride reduction of -1.0 mmol/L, with a p-value of 0.7, falling well below Sionna's projected 10 mmol/L improvement threshold. As a result, Sionna has decided not to advance SION-719 as an add-on treatment to standard care. Vertex's pipeline includes Atumelnant, a drug projected to compete with Crenessity, a treatment for congenital adrenal hyperplasia.
Bernstein's coverage expansion prompted Walch's reassessment, which also highlighted Vertex's Alyftrek as a key long-term asset. The drug's loss of exclusivity is not expected until 2038, providing the company with extended market leadership. Walch's note underscores Vertex's dominance in cystic fibrosis treatment while signaling confidence in its broader pipeline amid competitive pressures.
